Dosimetric model for locoregional treatments of brain tumors with 90Y-conjugates: Clinical application with 90Y-DOTATOC

Journal of Nuclear Medicine

Volumn 47, Issue 1, 2006, Pages 105-112

  Ferrari, Mahila ^a   Cremonesi, Marta ^a   Bartolomei, Mirco ^a   Bodei, Lisa ^a   Chinol, Marco ^a   Fiorenza, Maurizio ^a   Tosi, Giampiero ^a   Paganelli, Giovanni ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

90Y; Brain tumor; Locoregional treatment; Radiation dosimetry

Indexed keywords

(1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID,DEXTRO PHENYLALANINE 1,TYROSINE 3)OCTREOTIDE Y 90; UNCLASSIFIED DRUG; YTTRIUM 90; 90Y OCTREOTIDE, DOTA TYR(3); 90Y-OCTREOTIDE, DOTA-TYR(3)-; DRUG DERIVATIVE; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; DRUG ACTIVITY; DRUG DISTRIBUTION; FEMALE; HUMAN; MALE; NEUROIMAGING; PRIORITY JOURNAL; RADIATION DOSE; BIOLOGICAL MODEL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER SIMULATION; INTRALESIONAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MIDDLE AGED; RADIOMETRY; RELATIVE BIOLOGIC EFFECTIVENESS;

ADULT; AGED; BRAIN NEOPLASMS; COMPUTER SIMULATION; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OCTREOTIDE; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, COMPUTER-ASSISTED; RELATIVE BIOLOGICAL EFFECTIVENESS;

EID: 33746567103     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011-1018.
2. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572-2578.
3. Larson DA. Wara WM. Radiotherapy of primary malignant brain tumors. Semin Surg Oncol. 1998;14:34-42.
4. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693-713.
5. Zalutsky MR. Targeted radiotherapy of brain tumours. Br J Cancer. 2004;90:1469-1473.
6. 90Y-biotin in glioma patient: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm. 2001;16:227-235.
7. 3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res. 1999;5:1025-1033.
8. Riva P, Franceschi G, Riva N, et al. Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med. 2000;27:601-609.
9. 90Y-labelled radiopeptides. Eur J Nucl Med Mol Imaging. 2002;29:1697-1698.
10. Hopkins K, Chandler C, Bullimore J, et al. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiother Oncol. 1995;34:121-134.
11. Carnemolla B, Castellani P, Ponassi M, et al. Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol. 1999;154:1345-1352.
12. 3-octreotide (DOTATOC). Swiss Med Wkly. 2001;131(43-44):640-644.
13. Hopkins K, Papanastassiou V, Zananiri FA, et al. A model to estimate the dose to tumor following intracavity administration of radioimmunoconjugates to patients with malignant gliomas. Br J Radiol. 1997;70:1152-1161.
14. Snyder WS, Ford MR, Warner GG, et al. MIRD Pamphlet No. 11. "S" Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs. New York, NY: Society of Nuclear Medicine; 1975.
15. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys 2003;85:294-310.
16. Fassò A, Ferrari A, Ranft J, et al. An Update About FLUKA Proceedings of the 2nd Workshop on Simulating Accelerator Radiation Environments: CERN Report TIS-RP/97-05. In: Stevenson GR, ed. CERN: Geneva, Switzerland, October 9-11, 1995:158-170.
17. International Commission on Radiation Units and Measurements. Dosimetry of External Beta Rays for Radiation Protection. ICRU Report 56. Bethesda, MD: ICRU Publications; 1997.
18. International Commission on Radiological Protection. Reference Man: Anatomical, Physiological and Metabolic Characteristics. ICRP Publication 23. Oxford, U.K.: Pergamon Press; 1976.
19. International Commission on Radiation Units and Measurements. Phantom and Computational Models in Therapy, Diagnosis and Protection. ICRU Report 48. Bethesda, MD: ICRU Publications; 1992.
20. Torsen, Moller B, Reif E. Pocket Atlas of Cross-Sectional Anatomy: CT and MRI. Vol I. Stuttgart, Germany: Thieme Medical Publishers, Inc.; 2000.
21. Robbins SL, Lottrum RS, eds. Pathologic Basis of Disease. Philadelphia, PA: Saunders; 1979:1568.
22. 1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci. 1991;49:1583-1591.
23. 90Y-DOTATOC. Eur J Nucl Med. 1999;26:877-886.
24. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
25. Thomas SR, Stabin MG, Chen CT, et al. MIRD Pamphlet No. 14: a dynamic urinary bladder model for radiation dose calculations. J Nucl Med. 1992;33:783-802.
26. 131I-monoclonal antibodies for the treatment of central nervous system malignancies. Int J Radiat Oncol Biol Phys. 1995;31:541-552.
27. Behr TM, Behe M, Sgouros G. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. Cancer Biother Radiopharm. 2002;17:445-464.
28. Rand RW, Kreitman RJ, Patronas N, et al. Puri RK. Intratumoral administration of recombinant circulatory permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res. 2000;6:2157-2165.
29. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg. 1989;70:175-182.
30. Boiardi A, SalmaggiA, Pozzi A, et al. Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data. J Neurooncol. 1996;27:157-162.
31. 90Y: a phase I study. Clin Cancer Res. 1999;5(suppl):3275s- 3280s.
32. Cokgor I, Akabani G, Kuan CT. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2000;18:3862-3872.
33. Merlo A, Mueller-Brand J, Maecke HR. Comparing monoclonal antibodies and small peptidic hormones for local targeting of malignant gliomas. Acta Neurochir Suppl. 2003;88:83-91.
34. Reubi JC, Horisberger U, Lang W, Koper JW, Braakman R, Lamberts SWJ. Coincidence of EGF receptor and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol. 1989;134:337-344.
35. 90Y MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma: a model to estimate absorbed radiation dose. Br J Radiat Oncol Biol Phys. 1998;40:835-844.
36. 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging. 2002;29:486-493.
37. Dale R. Dose-rate effects in targeted radiotherapy. Phys Med Biol. 1996;41:1871-1884.
38. Dale R. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. Cancer Biother Radiopharm. 2004;19:363-370.
39. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med. 2005;46(suppl):4S-12S.